|View printer-friendly version|
Data to be presented at the
The investigators assessed anatomical expression of VE-PTP and Tie2 in the ocular outflow pathway and tested the effect of topical ocular administration AKB-9778 on IOP in a normotensive mouse animal model. Microscopic analysis showed co-expression of VE-PTP and Tie2 in endothelium of Schlemm’s canal, which drains the anterior chamber of the eye, and collector channels originating from Schlemm’s canal. Thus, the anatomical localization of Tie2 in Schlemm’s canal coincides with the region of pathogenesis of ocular hypertension in glaucoma that could be caused by Tie2 dysfunction. When an inhibitor of VE-PTP, AKB-9778, which activates the Tie2 pathway, is administered to the eye surface it induces a significant reduction of IOP as well as increased outflow through Schlemm’s canal. The study supports evaluating agents that activate Tie2 as a therapeutic approach to treating open-angle glaucoma.
“This study provides mechanistic proof-of-concept that the Tie2 pathway
is a valid therapeutic target to treat ocular hypertension in glaucoma
and that topical administration of AKP-9778, a potent VE-PTP inhibitor
and Tie2 activator, can significantly decrease intraocular pressure or
Abstract Title: By targeting Tie2/VE-PTP in Schlemm’s canal, AKB-9778 lowers intraocular pressure via increasing outflow facility in mice
Session Title: Aqueous humor dynamics and IOP
Session Date and Time: Monday, April 29, 2019 from 4:00 p.m. – 5:45 p.m. PDT
Presentation Number: 2186
Presentation Date and Time: Monday, April 29, 2019 from 4:00 p.m. – 4:15 p.m. PDT
Presenter: W. Daniel Stamer, Ph.D., Joseph A. C. Wadsworth Professor of Ophthalmology, Professor of Biomedical Engineering, Duke University
Location: Vancouver Convention Center Room East 2/3
Authors: W Daniel Stamer1, Guorong Li1, Iris D. Navarro1, Astrid Nottebaum2, Dietmar Vestweber2, Kevin G. Peters3
Affiliations: 1Ophthalmology, Duke University, Durham, North Carolina, United States; 2Max Planck Institute, Germany; 3Aerpio Pharmaceuticals, Ohio, United States
Abstracts and full session details can be found at www.arvo.org.
Forward Looking Statements
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the development of the Company’s product candidates, including AKB-9778, the Company’s plans for future development of its product candidates, including the timing and commencement of the Company’s planned clinical trials, the role of VE-PTP and the Tie2 pathway in treatment of diabetic complications, including ocular hypertension in glaucoma, and the therapeutic potential of the Company’s product candidates. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, the ability to continue to develop AKB-9778 or other product candidates, the inherent uncertainties associated with the drug development process, including uncertainties in regulatory interactions, commencing clinical trials and enrollment of patients in clinical trials, competition in the industry in which the Company operates and overall market conditions.
These forward-looking statements are made as of the date of this press
release, and the Company assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking statements,
except as required by law. Investors should consult all the information
set forth herein and should also refer to the risk factor disclosure set
forth in the reports and other documents the Company files with the
Investor & Media:
Aerpio Pharmaceuticals, Inc.
Chief Financial Officer
Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Nancie Steinberg / Robert Flamm, Ph.D.
firstname.lastname@example.org / email@example.com